These approaches could lead to the development of IL-12 immunotherapies that have important implications for the treatment of many different types of cancer in the years ahead. Stacy R.

Microbiotica’s MB097, an oral microbiome-based therapy, shows promise in boosting immunotherapy response in melanoma patients ...

GEN-1013 was studied in an aggressive CT26 murine cancer model using both IT and IV administration.Significant tumor reduction was observed in both administration routes. Both IT and IV were ...

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced ...

A new implant safely triggers potent immune responses against hard-to-treat cancers showing "promise" for pancreatic and ...

Strand Therapeutics Inc., the programmable mRNA company developing curative therapies for cancer and beyond, will present ...

The cancer-fighting device safely triggers "potent ... a critical need in the treatment of particularly aggressive cancers.

Zai Lab (ZLAB) will present new data from studies evaluating two of its internally developed, next-generation, investigational oncology ...

In preclinical studies using an aggressive CT26 murine cancer model ... s potential as a transformative therapy for solid tumors, leveraging localized IL-12 expression to stimulate potent immune ...